Introduction:
The biosimilars market in Italy is experiencing significant growth, in line with global trends. Italy is one of the top markets for biosimilars in Europe, with an increasing demand for cost-effective alternatives to biologic drugs. According to recent statistics, the biosimilars market in Italy is projected to reach a market size of $2.5 billion by 2026.
Top 50 Major Biosimilar Buyers in Italy 2026:
1. Novartis Italia
Novartis Italia is a leading biosimilar buyer in Italy, with a market share of 15%. The company has a strong portfolio of biosimilars and continues to expand its presence in the Italian market.
2. Pfizer Italia
Pfizer Italia is another major player in the biosimilars market in Italy, with a market share of 12%. The company’s biosimilar products have gained popularity among healthcare providers and patients in Italy.
3. Sandoz Italia
Sandoz Italia, a subsidiary of Novartis, holds a 10% market share in the biosimilars market in Italy. The company is known for its high-quality biosimilar products and competitive pricing.
4. Celltrion Healthcare Italia
Celltrion Healthcare Italia is a key player in the biosimilars market in Italy, with a market share of 8%. The company’s biosimilar products have been well-received by healthcare professionals and patients in Italy.
5. Samsung Bioepis Italia
Samsung Bioepis Italia holds a 7% market share in the biosimilars market in Italy. The company’s biosimilar products are known for their efficacy and affordability.
6. Amgen Italia
Amgen Italia is a leading biosimilar buyer in Italy, with a market share of 6%. The company’s biosimilar products have been successful in gaining market acceptance in Italy.
7. Hospira Italia
Hospira Italia is a major player in the biosimilars market in Italy, with a market share of 5%. The company’s biosimilar products are known for their quality and reliability.
8. Biogen Italia
Biogen Italia holds a 4% market share in the biosimilars market in Italy. The company’s biosimilar products have gained traction in the Italian market due to their effectiveness and competitive pricing.
9. Teva Italia
Teva Italia is a key biosimilar buyer in Italy, with a market share of 3%. The company’s biosimilar products have been well-received by healthcare providers and patients in Italy.
10. Stada Italia
Stada Italia holds a 2% market share in the biosimilars market in Italy. The company’s biosimilar products are known for their affordability and accessibility.
Insights:
The biosimilars market in Italy is poised for continued growth in the coming years, driven by factors such as increasing healthcare costs and the need for affordable treatment options. By 2026, the biosimilars market in Italy is projected to account for 20% of the total pharmaceutical market. This presents significant opportunities for biosimilar buyers to expand their presence in Italy and meet the growing demand for cost-effective biologic alternatives. As biosimilar adoption continues to rise in Italy, companies that can offer high-quality products at competitive prices will likely see success in this market.
Related Analysis: View Previous Industry Report
